Alembic Gears For Derma Push With New JV
This article was originally published in Scrip
Executive Summary
Shares of Alembic Pharmaceuticals spurted on Indian bourses on April 21 after the firm said that it had formed a joint venture with the privately held Orbicular Pharmaceutical Technologies and one of its founders, Dr MS Mohan, for dermatology products.
You may also be interested in...
Alembic Setting Up For US Oncology Play
Alembic Pharmaceuticals, which has seen a dazzling FY16, appears set to build on its strong showing in the US with plans for filings in the oncology and dermatology space and a potential ramp up of its own label products there.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet